Literature DB >> 22889558

Synthesis, chemical and enzymatic hydrolysis, and aqueous solubility of amino acid ester prodrugs of 3-carboranyl thymidine analogs for boron neutron capture therapy of brain tumors.

Sherifa Hasabelnaby1, Ayman Goudah, Hitesh K Agarwal, Mosaad S M abd Alla, Werner Tjarks.   

Abstract

Various water-soluble L-valine-, L-glutamate-, and glycine ester prodrugs of two 3-Carboranyl Thymidine Analogs (3-CTAs), designated N5 and N5-2OH, were synthesized for Boron Neutron Capture Therapy (BNCT) of brain tumors since the water solubilities of the parental compounds proved to be insufficient in preclinical studies. The amino acid ester prodrugs were prepared and stored as hydrochloride salts. The water solubilities of these amino acid ester prodrugs, evaluated in phosphate buffered saline (PBS) at pH 5, pH 6 and pH 7.4, improved 48-6600 times compared with parental N5 and N5-2OH. The stability of the amino acid ester prodrugs was evaluated in PBS at pH 7.4, Bovine serum, and Bovine cerebrospinal fluid (CSF). The rate of the hydrolysis in all three incubation media depended primarily on the amino acid promoiety and, to a lesser extend, on the site of esterification at the deoxyribose portion of the 3-CTAs. In general, 3'-amino acid ester prodrugs were less sensitive to chemical and enzymatic hydrolysis than 5'-amino acid ester prodrugs and the stabilities of the latter decreased in the following order: 5'-valine > 5'-glutamate > 5'-glycine. The rate of the hydrolysis of the 5'-amino acid ester prodrugs in Bovine CSF was overall higher than in PBS and somewhat lower than in Bovine serum. Overall, 5'-glutamate ester prodrug of N5 and the 5'-glycine ester prodrugs of N5 and N5-2OH appeared to be the most promising candidates for preclinical BNCT studies.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22889558      PMCID: PMC3432695          DOI: 10.1016/j.ejmech.2012.07.033

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  29 in total

1.  Synthesis, stability, and pharmacological evaluation of nipecotic acid prodrugs.

Authors:  F P Bonina; L Arenare; F Palagiano; A Saija; F Nava; D Trombetta; P de Caprariis
Journal:  J Pharm Sci       Date:  1999-05       Impact factor: 3.534

2.  Factors influencing solvolysis of corticosteroid-21-phosphate esters.

Authors:  G L Flynn; D J Lamb
Journal:  J Pharm Sci       Date:  1970-10       Impact factor: 3.534

3.  Unusually strong lipophilicity of 'fat' or 'super' amino-acids, including a new reference value for glycine.

Authors:  J L Fauchère; K Q Do; P Y Jow; C Hansch
Journal:  Experientia       Date:  1980-10-15

4.  Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport.

Authors:  Xueqin Song; Philip L Lorenzi; Christopher P Landowski; Balvinder S Vig; John M Hilfinger; Gordon L Amidon
Journal:  Mol Pharm       Date:  2005 Mar-Apr       Impact factor: 4.939

Review 5.  Boron neutron capture therapy of cancer: current status and future prospects.

Authors:  Rolf F Barth; Jeffrey A Coderre; M Graça H Vicente; Thomas E Blue
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

6.  Synthesis of 5-(carboranylalkylmercapto)-2'-deoxyuridines and 3-(carboranylalkyl)thymidines and their evaluation as substrates for human thymidine kinases 1 and 2.

Authors:  A J Lunato; J Wang; J E Woollard; A K Anisuzzaman; W Ji; F G Rong; S Ikeda; A H Soloway; S Eriksson; D H Ives; T E Blue; W Tjarks
Journal:  J Med Chem       Date:  1999-08-26       Impact factor: 7.446

7.  Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: interactions with the neutral and cationic amino acid transporter on the corneal epithelium.

Authors:  Banmeet S Anand; Suresh Katragadda; Yasser E Nashed; Ashim K Mitra
Journal:  Curr Eye Res       Date:  2004 Aug-Sep       Impact factor: 2.424

8.  Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors.

Authors:  Rolf F Barth; Weilian Yang; Ashraf S Al-Madhoun; Jayaseharan Johnsamuel; Youngjoo Byun; Subhash Chandra; Duane R Smith; Werner Tjarks; Staffan Eriksson
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

9.  Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine].

Authors:  L Colla; E De Clercq; R Busson; H Vanderhaeghe
Journal:  J Med Chem       Date:  1983-04       Impact factor: 7.446

Review 10.  Mammalian deoxyribonucleoside kinases.

Authors:  E S Arnér; S Eriksson
Journal:  Pharmacol Ther       Date:  1995       Impact factor: 12.310

View more
  10 in total

1.  Targeting (cellular) lysosomal acid ceramidase by B13: design, synthesis and evaluation of novel DMG-B13 ester prodrugs.

Authors:  Aiping Bai; Zdzislaw M Szulc; Jacek Bielawski; Jason S Pierce; Barbara Rembiesa; Silva Terzieva; Cungui Mao; Ruijuan Xu; Bill Wu; Christopher J Clarke; Benjamin Newcomb; Xiang Liu; James Norris; Yusuf A Hannun; Alicja Bielawska
Journal:  Bioorg Med Chem       Date:  2014-10-22       Impact factor: 3.641

Review 2.  Amino Acids in the Development of Prodrugs.

Authors:  Nuno Vale; Abigail Ferreira; Joana Matos; Paula Fresco; Maria João Gouveia
Journal:  Molecules       Date:  2018-09-11       Impact factor: 4.411

3.  Cellular influx, efflux, and anabolism of 3-carboranyl thymidine analogs: potential boron delivery agents for neutron capture therapy.

Authors:  Elena Sjuvarsson; Vijaya L Damaraju; Delores Mowles; Michael B Sawyer; Rohit Tiwari; Hitesh K Agarwal; Ahmed Khalil; Sherifa Hasabelnaby; Ayman Goudah; Robin J Nakkula; Rolf F Barth; Carol E Cass; Staffan Eriksson; Werner Tjarks
Journal:  J Pharmacol Exp Ther       Date:  2013-09-04       Impact factor: 4.030

4.  Synthesis and evaluation of thymidine kinase 1-targeting carboranyl pyrimidine nucleoside analogs for boron neutron capture therapy of cancer.

Authors:  Hitesh K Agarwal; Ahmed Khalil; Keisuke Ishita; Weilian Yang; Robin J Nakkula; Lai-Chu Wu; Tehane Ali; Rohit Tiwari; Youngjoo Byun; Rolf F Barth; Werner Tjarks
Journal:  Eur J Med Chem       Date:  2015-05-27       Impact factor: 6.514

Review 5.  Boron Chemicals in Drug Discovery and Development: Synthesis and Medicinal Perspective.

Authors:  Bhaskar C Das; Nitesh K Nandwana; Sasmita Das; Varsha Nandwana; Mohammed Adil Shareef; Yogarupa Das; Mariko Saito; Louis M Weiss; Frankis Almaguel; Narayan S Hosmane; Todd Evans
Journal:  Molecules       Date:  2022-04-19       Impact factor: 4.927

Review 6.  Boron chemicals in diagnosis and therapeutics.

Authors:  Bhaskar C Das; Pritam Thapa; Radha Karki; Caroline Schinke; Sasmita Das; Suman Kambhampati; Sushanta K Banerjee; Peter Van Veldhuizen; Amit Verma; Louis M Weiss; Todd Evans
Journal:  Future Med Chem       Date:  2013-04       Impact factor: 3.808

Review 7.  N3-substituted thymidine bioconjugates for cancer therapy and imaging.

Authors:  Ahmed Khalil; Keisuke Ishita; Tehane Ali; Werner Tjarks
Journal:  Future Med Chem       Date:  2013-04       Impact factor: 3.808

8.  Synthesis of N3-substituted carboranyl thymidine bioconjugates and their evaluation as substrates of recombinant human thymidine kinase 1.

Authors:  Hitesh K Agarwal; Craig A McElroy; Elena Sjuvarsson; Staffan Eriksson; Michael V Darby; Werner Tjarks
Journal:  Eur J Med Chem       Date:  2012-12-05       Impact factor: 6.514

9.  Multi-small molecule conjugations as new targeted delivery carriers for tumor therapy.

Authors:  Lingling Shan; Ming Liu; Chao Wu; Liang Zhao; Siwen Li; Lisheng Xu; Wengen Cao; Guizhen Gao; Yueqing Gu
Journal:  Int J Nanomedicine       Date:  2015-09-01

Review 10.  The Boron Advantage: The Evolution and Diversification of Boron's Applications in Medicinal Chemistry.

Authors:  Katia Messner; Billy Vuong; Geoffrey K Tranmer
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.